Skip to Content

Generic Nuplazid Availability

Nuplazid is a brand name of pimavanserin, approved by the FDA in the following formulation(s):

NUPLAZID (pimavanserin tartrate - tablet;oral)

  • Manufacturer: ACADIA PHARMS INC
    Approval date: April 29, 2016
    Strength(s): EQ 17MG BASE [RLD]

Has a generic version of Nuplazid been approved?

No. There is currently no therapeutically equivalent version of Nuplazid available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nuplazid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Azacyclic compounds
    Patent 6,756,393
    Issued: June 29, 2004
    Inventor(s): Carl-Magnus A.; Andersson & Glenn; Croston & Eva L.; Hansen & Allan Kjaersgaard; Uldam
    Assignee(s): Acadia Pharmaceuticals, Inc.
    Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.
    Patent expiration dates:
    • March 6, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Azacyclic compounds
    Patent 6,815,458
    Issued: November 9, 2004
    Inventor(s): Carl-Magnus A.; Andersson & Glenn; Croston & Eva Louise; Hansen & Allan Kjaersgaard; Uldam
    Assignee(s): Acadia Pharmaceuticals, Inc
    Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.
    Patent expiration dates:
    • March 6, 2021
      ✓ 
      Patent use: TREATMENT OF PSYCHOSIS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • 4-aminopiperidine and their use as a medicine
    Patent 7,115,634
    Issued: October 3, 2006
    Inventor(s): Thurieau; Christophe & Gonzalez; Jérôme & Moinet; Christophe
    Assignee(s): Societe de Conseils de Recherches et d'Applications Scientifiques
    A subject of the present application is new derivatives of 4-aminopiperidines of formula in which R1, R2 and R3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) somatostatin receptors are involved.
    Patent expiration dates:
    • October 6, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
    Patent 7,601,740
    Issued: October 13, 2009
    Inventor(s): Weiner; David M. & Davis; Robert E. & Brann; Mark R. & Andersson; Carl-Magnus A. & Uldam; Allan K.
    Assignee(s): Acadia Pharmaceuticals, Inc.
    Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
    Patent expiration dates:
    • June 17, 2027
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
    Patent 7,659,285
    Issued: February 9, 2010
    Inventor(s): Weiner; David M. & Davis; Robert E. & Brann; Mark R. & Andersson; Carl-Magnus A. & Uldam; Allan K.
    Assignee(s): Acadia Pharmaceuticals, Inc.
    Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
    Patent expiration dates:
    • August 24, 2026
      ✓ 
      Patent use: TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS
  • N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
    Patent 7,732,615
    Issued: June 8, 2010
    Inventor(s): Thygesen; Mikkel Boas & Schlienger; Nathalie & Tolf; Bo-Ragnar & Andersson; Carl-Magnus A. & Blatter; Fritz & Berghausen; Jörg
    Assignee(s): ACADIA Pharmaceuticals Inc.
    Disclosed herein are methods for synthesizing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide. Also disclosed herein is the hemi-tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2 -methylpropyloxy)-phenylmethyl)carbamide and methods for obtaining the salt. Further disclosed are various crystalline forms of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide and its hemi-tartrate salt including various polymorphs and solvates.
    Patent expiration dates:
    • June 3, 2028
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Derivatives of 4-aminopiperidine and their use as a medicament
    Patent 7,858,789
    Issued: December 28, 2010
    Inventor(s): Thurieau; Christophe & Gonzalez; Jérôme & Moinet; Christophe
    Assignee(s): Ipsen Pharma S.A.S.
    A subject of the present application is new derivatives of 4-aminopiperidines of formula in which R1, R2 and R3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) somatostatin receptors are involved.
    Patent expiration dates:
    • December 13, 2020
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms
    Patent 7,923,564
    Issued: April 12, 2011
    Inventor(s): Thygesen; Mikkel Boas & Schlienger; Nathalie & Tolf; Bo-Ragnar & Andersson; Carl-Magnus A. & Blatter; Fritz & Berghausen; Jörg
    Assignee(s): ACADIA Pharmaceuticals, Inc.
    Disclosed herein are methods for synthesizing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide. Also disclosed herein is the hemi-tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide and methods for obtaining the salt. Further disclosed are various crystalline forms of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide and its hemi-tartrate salt including various polymorphs and solvates.
    Patent expiration dates:
    • September 26, 2025
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Derivatives of 4-aminopiperidine and their use as a medicament
    Patent 8,110,574
    Issued: February 7, 2012
    Inventor(s): Thurieau; Christophe & Gonzalez; Jérôme & Moinet; Christophe
    Assignee(s): Ipsen Pharma S.A.S.
    A subject of the present application is new derivatives of 4-aminopiperidines of formula in which R1, R2 and R3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) somatostatin receptors are involved.
    Patent expiration dates:
    • December 13, 2020
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
    Patent 8,618,130
    Issued: December 31, 2013
    Assignee(s): ACADIA Pharmaceuticals Inc.
    Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
    Patent expiration dates:
    • January 15, 2024
      ✓ 
      Patent use: TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF
  • Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
    Patent 8,921,393
    Issued: December 30, 2014
    Assignee(s): ACADIA Pharmaceuticals Inc.
    Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
    Patent expiration dates:
    • January 15, 2024
      ✓ 
      Patent use: TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF
  • Azacyclic compounds
    Patent 9,296,694
    Issued: March 29, 2016
    Assignee(s): ACADIA PHARMACEUTICALS INC.
    Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.
    Patent expiration dates:
    • March 6, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 29, 2021 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide